1. Home
  2. CYCU vs PMCB Comparison

CYCU vs PMCB Comparison

Compare CYCU & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$0.63

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.77

Market Cap

8.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
PMCB
Founded
2017
1996
Country
United States
United States
Employees
74
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
8.2M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
CYCU
PMCB
Price
$0.63
$0.77
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
602.4K
130.4K
Earning Date
06-05-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
277.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.92
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.63
52 Week High
$7.13
$1.51

Technical Indicators

Market Signals
Indicator
CYCU
PMCB
Relative Strength Index (RSI) 34.56 51.11
Support Level $0.58 $0.66
Resistance Level $1.05 $0.78
Average True Range (ATR) 0.07 0.05
MACD -0.01 0.00
Stochastic Oscillator 10.58 61.23

Price Performance

Historical Comparison
CYCU
PMCB

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: